2 assets in Peritoneal Serous Adenocarcinoma

Therapeutic assets addressing Peritoneal Serous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lenvatinib Peritoneal Serous Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Pembrolizumab Peritoneal Serous Adenocarcinoma	M.D. Anderson Cancer Center	P2	CCC (53)